7,933 Shares in Revolution Medicines, Inc. $RVMD Acquired by Flax Pond Capital LLC

Flax Pond Capital LLC acquired a new stake in shares of Revolution Medicines, Inc. (NASDAQ:RVMD) in the fourth quarter, according to the company in its most recent disclosure with the SEC. The firm acquired 7,933 shares of the company’s stock, valued at approximately $632,000.

A number of other large investors have also added to or reduced their stakes in the stock. Vanguard Group Inc. increased its holdings in shares of Revolution Medicines by 6.7% during the fourth quarter. Vanguard Group Inc. now owns 16,719,886 shares of the company’s stock valued at $1,331,739,000 after acquiring an additional 1,056,792 shares in the last quarter. Mirae Asset Global Investments Co. Ltd. boosted its stake in Revolution Medicines by 194.6% in the 4th quarter. Mirae Asset Global Investments Co. Ltd. now owns 21,289 shares of the company’s stock worth $1,696,000 after purchasing an additional 14,062 shares in the last quarter. Raiffeisen Bank International AG purchased a new stake in Revolution Medicines during the 3rd quarter valued at about $921,000. Mass General Brigham Inc purchased a new stake in Revolution Medicines during the 4th quarter valued at about $27,407,000. Finally, M&T Bank Corp bought a new stake in Revolution Medicines during the 4th quarter valued at about $52,723,000. Hedge funds and other institutional investors own 94.34% of the company’s stock.

Analyst Upgrades and Downgrades

Several brokerages have issued reports on RVMD. Piper Sandler lifted their target price on shares of Revolution Medicines to $172.00 and gave the stock an “overweight” rating in a report on Thursday, May 7th. UBS Group started coverage on shares of Revolution Medicines in a report on Friday, February 27th. They set a “buy” rating on the stock. Stifel Nicolaus reissued a “buy” rating on shares of Revolution Medicines in a research report on Monday, April 20th. Truist Financial began coverage on shares of Revolution Medicines in a report on Monday, May 18th. They issued a “buy” rating and a $179.00 price objective for the company. Finally, Royal Bank Of Canada upped their price objective on Revolution Medicines from $165.00 to $182.00 and gave the company an “outperform” rating in a research report on Tuesday, June 2nd. Three research analysts have rated the stock with a Strong Buy rating, seventeen have assigned a Buy rating, one has given a Hold rating and one has issued a Sell rating to the company’s stock. According to MarketBeat.com, the stock has an average rating of “Buy” and an average price target of $123.72.

Revolution Medicines Price Performance

Shares of NASDAQ:RVMD opened at $162.99 on Friday. The company has a quick ratio of 6.80, a current ratio of 6.80 and a debt-to-equity ratio of 0.19. Revolution Medicines, Inc. has a twelve month low of $34.00 and a twelve month high of $166.50. The stock has a market capitalization of $34.65 billion, a PE ratio of -23.05 and a beta of 1.40. The firm’s 50 day moving average price is $147.04 and its 200-day moving average price is $113.34.

Revolution Medicines (NASDAQ:RVMD) last posted its quarterly earnings data on Wednesday, May 6th. The company reported ($2.29) earnings per share for the quarter, missing analysts’ consensus estimates of ($1.83) by ($0.46). During the same quarter in the previous year, the firm earned ($1.13) earnings per share. Equities research analysts expect that Revolution Medicines, Inc. will post -7.94 EPS for the current year.

Insiders Place Their Bets

In other Revolution Medicines news, insider Mark A. Goldsmith sold 120,000 shares of the company’s stock in a transaction that occurred on Wednesday, April 15th. The stock was sold at an average price of $150.09, for a total value of $18,010,800.00. Following the completion of the transaction, the insider directly owned 276,698 shares in the company, valued at $41,529,602.82. This represents a 30.25% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available through the SEC website. Also, COO Margaret A. Horn sold 60,400 shares of the company’s stock in a transaction on Monday, June 15th. The stock was sold at an average price of $160.17, for a total transaction of $9,674,268.00. Following the transaction, the chief operating officer owned 158,222 shares of the company’s stock, valued at approximately $25,342,417.74. This represents a 27.63% decrease in their position. The SEC filing for this sale provides additional information. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Over the last quarter, insiders have sold 226,917 shares of company stock valued at $35,065,702. 7.60% of the stock is owned by company insiders.

Revolution Medicines Profile

Revolution Medicines is a clinical-stage biopharmaceutical company focused on discovering and developing small molecule therapies to treat RAS-dependent cancers and other diseases driven by the RAS/MAPK pathway. The company’s research efforts target historically “undruggable” proteins, aiming to inhibit critical nodes in cell signaling that promote tumor growth and therapeutic resistance.

The lead pipeline includes RMC-4630, a SHP2 inhibitor; RMC-6291, a selective KRAS G12C inhibitor; and RMC-6236, a pan-RAS inhibitor designed to address multiple RAS mutations.